Author Affiliations: Department of Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia (Dr LaRiccia) (email@example.com); and Biomedical Library, University of Pennsylvania, Philadelphia (Dr Morgan).
To the Editor: In a meta-analysis of 25 randomized controlled trials, Ms Thompson and colleagues determined that pharmacological treatment of normotensive and prehypertensive patients for the secondary prevention of CVD events was associated with statistically significant decreases in stroke, congestive heart failure (CHF), composite CVD outcomes, and all-cause mortality.1 Are these statistically significant outcomes clinically significant from a patient's perspective or a public health perspective?
LaRiccia PJ, Morgan S. Antihypertensive Treatment of Patients With Cardiovascular Disease but Without Hypertension. JAMA. 2011;305(21):2170-2171. doi:10.1001/jama.2011.705